BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology (BMS_PD-L1)
Diffuse large B-cell lymphomas (DLBCLs) represent 25 to 30% of adult non-Hodgkin lymphomas in western countries. DLBCLs are aggressive cancer but potentially curable with multi-agent chemotherapy. Whereas R-CHOP regimen has led to a marked improvement in survival, this disease remains a biologically heterogeneous entity. New therapeutic strategies are required including identification of patients' subgroups with different prognostic.
This project is based on BMS_LyTrans and Goelams 075 clinical trial. A study of whole blood transcriptome in 75 DLBCL patients and in 87 controls showed that PD-L1 (CD274) gene was overexpressed in DLBCL patients. Preliminary results demonstrated that PD-L1 is detected in plasma of DLBCL patients with a significantly higher concentration than in controls. This protein was selected as a potential biomarker because of its established role in anti-tumoral immunity. Interaction between PD-L1 and its receptor PD-1 is known to inhibit activation of immune responses by inducing T-lymphocytes anergy and/or apoptosis. Moreover, a direct involvement of PD-L1 in the protection of cancer cells from lysis by activated T lymphocytes has been demonstrated. PD-L1 expression has been described in several solid tumours, including ovary cancer, breast cancer, colon cancer, renal cell carcinoma, non-small cell lung carcinoma and in hematological malignancies such as T-NHL, MM and Hodgkin's lymphoma. Furthermore the expression of PD-L1 by tumour cells is associated with poor prognosis. The blockade of PD-L1/PD-1 axis may represent a novel therapeutic approach in aggressive cancers. These first results incite to identify the cells releasing soluble PD-L1 and to investigate its role in the anti-tumoral immunity in DLBCL patients.
The aim of this study is to identify cells producing soluble PD-L1 in DLBCL patients at diagnosis in comparison to others tumours known to express PD-L1 (metastatic breast cancer, Hodgkin's lymphoma, non-small cell lung cancer).
研究概览
地位
详细说明
Secondary purposes are :
- To confirm the presence of plasma soluble form of PD-L1 in others malignancies
- To study surface expression of PD-L1 on circulating tumour cells with multiparameter fow cytometry and Veridex® technology in DLBCL and metastatic breast cancer patients
- To study surface expression of PD-L1 on circulating endothelial cells in DLBCL, Hodgkin lymphoma and metastatic breast cancer patients (subpart ended in late 2012)
- To study surface expression of PD-L1 on different types of leukocytes (monocytes, B and T lymphocytes)
- To separate circulating tumour cells expressing PD-L1 by immunomagnetic or Cell-sorting method
- To develop ELISPOT technique to study the release of soluble PD-L1 in culture supernatants of selected cells (subpart ended mid 2013)
- to evaluate the correlation between the expression of PD-L1 in the plasma and *) the expression of PD-L1 in the tumor, **) the expression of PD-L1 and other molecules in the bronchoalveolar liquid (whenever available from routine) in non-small cell lung cancer
- to evaluate the response to treatment according to plasma PD-L1 expression in non-small cell lung cancer
- to evaluate the susceptibility to develop a disease according to the single nucleotide polymorphisms of the PD-L1 gene in DLBCL and non-small cell lung cancer
- Constitution of the different cohorts and collection of samples Main cohort : de novo DLBCL at diagnosis Secondary cohorts: Hodgkin's lymphoma, metastatic breast cancer, non small cell lung cancer Control cohorts : healthy volunteers (blood donors), patients with immune thrombocytopenia (ITP)
- Quantification of plasma soluble PD-L1 in the different cohorts
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Marseille、法国、13000
- Institut Paoli Calmette
-
Montpellier、法国、34000
- Montpellier University Hospital
-
-
Brittanny
-
Rennes、Brittanny、法国、35000
- Rennes EFS
-
Rennes、Brittanny、法国、35000
- Rennes University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
General inclusion criteria :
- Age ≥ 18 years and ≤ 75 years,
- Life expectancy more than 4 months
- Signed informed consent obtained
- Social security affiliation is mandatory
- Non previously treated (even by corticotherapy),
- HIV negative, HBs negative, HCV negative
Inclusion criteria for DLBCL patients :
- A biopsy proven diagnosis of de novo DLBCL according to the current WHO criteria,
- Immunohistochemistry for GCB/nonGC classification according to Hans' algorithm
- Patients with advanced-stage disease defined as Ann Arbor stages III or IV, or stages I or II with bulky disease (>7cm)
Inclusion criteria for non-small cell lung cancer patients :
- A biopsy proven diagnosis of de novo non-small cell lung cancer (all stages) according to the current WHO criteria
Inclusion criteria for Hodgkin's lymphoma patients :
- A biopsy proven diagnosis of Hodgkin's lymphoma according to the current WHO criteria
Inclusion criteria for metastatic breast cancer or with lymph node involvement :
- A biopsy proven diagnosis infiltrating lobular or ductal breast carcinoma
- with lymph node involvement or metastasis
Inclusion criteria for patients with immune thrombocytopenia (ITP) :
- Primary ITP was defined by the IWG as a platelet count less than 100 G/L in the absence of other causes or disorders that may be associated with thrombocytopenia.
- Bone marrow examination excluding a central aetiology of thrombocytopenia
Inclusion criteria for healthy volunteers :
- Inclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria
Exclusion Criteria:
General non-inclusion criteria :
- Age < 18 years et > 75 years,
- Pregnant women,
- Person legally involved in a case
- No social security affiliation
- Signed informed consent not obtained,
- Preliminary treatment (even corticoid treatment).
- HIV positive, HBs positive, HCV positive
Non-inclusion criteria for DLBCL patients :
- Lymphoma other than DLBCL,
- Transformation of a low grade lymphoma to a high grade lymphoma (DLBCL),
- Extranodal marginal zone lymphoma of MALT lymphoma,
- Post-transplant lymphoproliferative disorders,
- Lymphoblastic lymphoma,
- Burkitt's lymphoma,
- Carcinoma or history of carcinoma except in situ cervical carcinoma.
Non-inclusion criteria for non-small cell lung cancer patients : None
Non-inclusion criteria for Hodgkin patients :
- Non Hodgkin's lymphoma
Non-inclusion criteria for metastatic breast cancer or with lymph node involvement :
- Carcinoma other than infiltrating lobular or ductal breast carcinoma
- Chemotherapy in 30 days preceding the inclusion
- Hormonotherapy in 7 days preceding the inclusion
- Carcinoma or history of carcinoma except in situ cervical carcinoma.
- Hemoglobin level < 10g/dl
Non-inclusion criteria for patients with immune thrombocytopenia (ITP) :
- Central aetiology of the thrombocytopenia
Non-inclusion criteria for healthy volunteers :
- Exclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
健康志愿者
|
|
DLBCL (diffuse large B-cell lymphoma)
|
|
Hodgkin's lymphoma
|
|
metastatic breast cancer
metastatic breast cancer or with lymph node involvement
|
|
immune thrombocytopenia (ITP)
|
|
non-small cell lung cancer
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin's lymphoma and non-small cell lung cancer
大体时间:4 years
|
Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin's lymphoma and non-small cell lung cancer
|
4 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Analysis of PD-L1 membrane protein expression on circulating tumor cells by multiparameter flow cytometry and Veridex® in DLBCL and metastatic breast cancer, and bone marrow tumor cells by flow cytometry in DLBCL
大体时间:4 years
|
Analysis of PD-L1 membrane protein expression on circulating tumor cells by multiparameter flow cytometry and Veridex® in DLBCL and metastatic breast cancer, and bone marrow tumor cells by flow cytometry in DLBCL
|
4 years
|
|
Analysis of PD-L1 membrane protein expression on circulating endothelial cells with the Veridex® technology in DLBCL, Hodgkin's lymphoma and metastatic breast cancer (subpart ended in late 2012)
大体时间:4 years
|
Analysis of PD-L1 membrane protein expression on circulating endothelial cells with the Veridex® technology in DLBCL, Hodgkin's lymphoma and metastatic breast cancer (subpart ended in late 2012)
|
4 years
|
|
Analysis of PD-L1 membrane protein expression on monocytes, B and T lymphocytes in all cohorts
大体时间:4 years
|
Analysis of PD-L1 membrane protein expression on monocytes, B and T lymphocytes in all cohorts
|
4 years
|
|
Development of an ELISPOT technique to detect soluble PD-L1 in the supernatants of sorted primary cells (subpart ended mid 2013)
大体时间:4 years
|
Development of an ELISPOT technique to detect soluble PD-L1 in the supernatants of sorted primary cells (subpart ended mid 2013)
|
4 years
|
|
Evaluation of the techniques (by immunomagnetic or cell-sorting) used to separate circulating tumor cells expressing PD-L1
大体时间:4 years
|
Evaluation of the techniques (by immunomagnetic or cell-sorting) used to separate circulating tumor cells expressing PD-L1
|
4 years
|
|
Correlation between the PD-L1 expression *) in the plasma, **) in the tumor and ***) in the bronchoalveolar liquid in non-small cell lung cancer
大体时间:4 years
|
Correlation between the PD-L1 expression *) in the plasma, **) in the tumor and ***) in the bronchoalveolar liquid in non-small cell lung cancer
|
4 years
|
|
Evaluation of the response to treatment according to soluble PD-L1 expression in non-small cell lung cancer
大体时间:4 years
|
Evaluation of the response to treatment according to soluble PD-L1 expression in non-small cell lung cancer
|
4 years
|
|
Evaluation of the susceptibility to develop a disease according to PD-L1 gene SNP in DLBCL and non-small cell lung cancer
大体时间:4 years
|
Evaluation of the susceptibility to develop a disease according to PD-L1 gene SNP in DLBCL and non-small cell lung cancer
|
4 years
|
合作者和调查者
调查人员
- 首席研究员:Thierry Fest, MD、Rennes University Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2011-A01163-38
- B111181-40 (其他标识符:AFSSAPS)
- 11/32-821 (其他标识符:CPP OUest V)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.